Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases

Purpose of ReviewIn this review, the impact of obesity on cardiovascular disease in women and emerging anti-obesity pharmacologic treatments are discussed.Recent FindingsRobust evidence demonstrates the burden of obesity across the lifespan in women and links obesity to a diverse set of cardiovascular diseases. Female-specific risk factors including sex hormones and pregnancy factors intersect with obesity and cardiovascular risk. Sustained weight loss has potential for cardiovascular benefits. Recent trials demonstrate cardiovascular benefits of emerging agents with weight loss effects including GLP-1 RA and SGLT2 inhibitors in women.SummaryTreatment and prevention strategies for cardiovascular disease in obese women should include integration of weight management strategies including the targeted use of emerging pharmacologic therapies.

Automated summary

This review discusses the impact of obesity on cardiovascular disease in women and the emerging anti-obesity pharmacologic treatments. The evidence shows that obesity burdens women across their lifespan and is linked to a variety of cardiovascular diseases. Female-specific risk factors, such as sex hormones and pregnancy factors, intersect with obesity and cardiovascular risk. Sustained weight loss has the potential for cardiovascular benefits. Recent trials demonstrate the cardiovascular benefits of emerging agents with weight loss effects, such as GLP-1 RA and SGLT2 inhibitors, in women.